HK1206246A1 - Use of high dose laquinimod for treating multiple sclerosis - Google Patents

Use of high dose laquinimod for treating multiple sclerosis Download PDF

Info

Publication number
HK1206246A1
HK1206246A1 HK15106789.5A HK15106789A HK1206246A1 HK 1206246 A1 HK1206246 A1 HK 1206246A1 HK 15106789 A HK15106789 A HK 15106789A HK 1206246 A1 HK1206246 A1 HK 1206246A1
Authority
HK
Hong Kong
Prior art keywords
treating
human patient
multiple sclerosis
human
presenting
Prior art date
Application number
HK15106789.5A
Other languages
English (en)
Chinese (zh)
Inventor
Bar-Zohar Dan
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1206246A1 publication Critical patent/HK1206246A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15106789.5A 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis HK1206246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02
US61/641,389 2012-05-02
PCT/US2013/039090 WO2013166166A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
HK1206246A1 true HK1206246A1 (en) 2016-01-08

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106789.5A HK1206246A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Country Status (21)

Country Link
US (3) US20130303569A1 (cg-RX-API-DMAC7.html)
EP (1) EP2844255A4 (cg-RX-API-DMAC7.html)
JP (2) JP2015515985A (cg-RX-API-DMAC7.html)
KR (1) KR20150013658A (cg-RX-API-DMAC7.html)
CN (2) CN105832733A (cg-RX-API-DMAC7.html)
AR (1) AR090885A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013256352A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014027010A2 (cg-RX-API-DMAC7.html)
CA (1) CA2870684A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014002935A1 (cg-RX-API-DMAC7.html)
EA (1) EA201492010A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206246A1 (cg-RX-API-DMAC7.html)
IL (1) IL235337A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014013039A (cg-RX-API-DMAC7.html)
PE (1) PE20150161A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502447A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201406594UA (cg-RX-API-DMAC7.html)
TW (2) TW201347762A (cg-RX-API-DMAC7.html)
UY (1) UY34775A (cg-RX-API-DMAC7.html)
WO (1) WO2013166166A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408820B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
TW201345527A (zh) 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013329348A1 (en) * 2012-10-12 2015-05-28 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症
EA201591699A1 (ru) 2013-03-14 2016-02-29 Тева Фармасьютикал Индастриз Лтд. Кристаллы лаквинимода натрия и улучшенный способ их производства
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
US20150306088A1 (en) * 2014-04-29 2015-10-29 Teva Pharmaceutical Industries, Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
WO2020016850A1 (en) * 2018-07-20 2020-01-23 Merck Patent Gmbh A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症

Also Published As

Publication number Publication date
US20160000775A1 (en) 2016-01-07
PH12014502447A1 (en) 2015-01-12
PE20150161A1 (es) 2015-02-22
AR090885A1 (es) 2014-12-10
UY34775A (es) 2013-11-29
CN104284663A (zh) 2015-01-14
CN105832733A (zh) 2016-08-10
US20130303569A1 (en) 2013-11-14
WO2013166166A1 (en) 2013-11-07
TW201804997A (zh) 2018-02-16
CL2014002935A1 (es) 2015-03-06
US20150265592A1 (en) 2015-09-24
IL235337A0 (en) 2014-12-31
TW201347762A (zh) 2013-12-01
MX2014013039A (es) 2015-02-04
KR20150013658A (ko) 2015-02-05
JP2015515985A (ja) 2015-06-04
CA2870684A1 (en) 2013-11-07
JP2017222691A (ja) 2017-12-21
EA201492010A1 (ru) 2015-06-30
EP2844255A4 (en) 2015-10-14
BR112014027010A2 (pt) 2017-06-27
SG11201406594UA (en) 2014-11-27
EP2844255A1 (en) 2015-03-11
ZA201408820B (en) 2016-06-29
AU2013256352A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
HK1198869A1 (en) Combination treatments for hepatitis c
NZ589445A (en) Rasagiline for parkinson's disease modification
NZ714963A (en) Compositions and methods for treating anemia
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201390827A1 (ru) Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом
HK1198278A1 (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
NZ605469A (en) Nalbuphine-based formulations and uses thereof
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
JP2016505050A5 (cg-RX-API-DMAC7.html)
UA115250C2 (uk) Фармацевтичні комбінації
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
WO2012125871A3 (en) Aconitine compounds, compositions, uses, and preparation thereof
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
NZ599227A (en) Therapeutic agent for chronic pain
WO2014064711A3 (en) Methods of administering raltegravir and raltegravir compositions